Drugs and Devices

FDA expands indication for continuous glucose monitoring system

On Dec. 20, the Food and Drug Administration (FDA) expanded the approved use of Dexcom’s G5 Mobile Continuous Glucose Monitoring System to allow for replacement of fingerstick blood glucose testing for diabetes treatment decisions in people 2 years of age and older with diabetes. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares